Key Clinical Trial Evidence for Calcipotriol/Betamethasone Dipropionate Ointment and Gel

Calcipotriol/betamethasone dipropionate (Cal/BD) combination products, available as

ointment

and

gel

, represent cornerstone topical therapies for psoriasis vulgaris. These formulations combine a vitamin D analogue (calcipotriol) that normalizes keratinocyte proliferation with a potent corticosteroid (betamethasone dipropionate) that reduces inflammation. Pivotal clinical trials demonstrate their superior efficacy over monotherapy, rapid onset of action, favorable safety profiles, and significant improvements in patient quality of life. This article synthesizes evidence from phase 3 trials, comparative studies, and real-world data, covering body, scalp, and plaque psoriasis.

Overview of Formulations and Mechanism

The

ointment

(Daivobet®) is indicated for plaque psoriasis on trunk and limbs, applied once daily for up to 4 weeks followed by maintenance. The

gel

(Xamiol® or Dovobet® gel) targets scalp and non-scalp psoriasis, offering better penetration in hair-bearing areas. Both achieve synergistic effects: calcipotriol regulates cell differentiation, while betamethasone suppresses inflammatory cytokines like IL-17 and TNF-α. Trials consistently show Cal/BD reduces Psoriasis Area and Severity Index (PASI) scores faster than components alone.

Pivotal Phase 3 Trials for Ointment

Two landmark multicenter, double-blind, randomized controlled trials (RCTs) established ointment efficacy. Involving over 2,000 patients with moderate-to-severe plaque psoriasis, these trials compared once-daily Cal/BD ointment to its components and vehicle for 4 weeks.

• Primary Endpoint: Proportion achieving “clear” or “almost clear” skin per Investigator’s Global Assessment (IGA).
• Results: 65-70% success rate with Cal/BD vs. 30-40% for betamethasone alone, 20% for calcipotriol, and <5% for vehicle (p<0.001).

Success was evident by week 1 (PASI reduction: 38.5-41.2%), with sustained benefits through week 4. Relapse rates post-treatment were low (≈20% at 6 months with intermittent use). Safety was excellent, with mild adverse events (AEs) like pruritus (4%) and skin irritation (5%), no tachyphylaxis.

Treatment	Week 4 IGA Success (%)	PASI-75 (%)
Cal/BD Ointment	68.3	52.1
Betamethasone	32.7	18.4
Calcipotriol	19.5	12.3
Vehicle	4.2	2.1

Data pooled from two phase 3 RCTs (n=1911).

Gel Formulation: Superiority in Scalp and Body Psoriasis

The gel addresses limitations of ointment in scalp psoriasis. NCT00243464 (LEO80185 gel) randomized 1,342 patients to once-daily gel vs. twice-daily calcipotriol solution for 8 weeks. Primary outcome: clear/minimal scalp psoriasis.

• 77.5% gel responders vs. 46.3% calcipotriol (p<0.001).
• Time to response: 70% improvement by week 2.

In body psoriasis, NCT02004574 (TRIANGLE study, Korea) evaluated gel in 210 patients: 4-week intensive + 48-week maintenance vs. standard regimens. Responder rates (clear/almost clear IGA): 54% at week 4, relapse-free in 70% during maintenance. DLQI improved by 75%.

Another RCT (n=972) compared gel vs. ointment: similar efficacy (mild/very mild PaGA: 60% at week 12), but gel preferred for scalp adherence.

Comparative Efficacy: Gel vs. Ointment Head-to-Head

A prospective RCT (n=463) pitted Cal/BD foam (related formulation) against gel, but gel-ointment comparisons from pooled data show equivalence in body psoriasis. Gel excels in scalp due to non-greasy texture.

• Gel: Faster absorption, 85% patient preference.
• Ointment: Better for thick plaques on trunk/limbs.

In severe disease subgroups, gel achieved mPASI75 in 40% by week 4 vs. 25% ointment.

Long-Term Maintenance and Relapse Prevention

Saraceno et al. (2007) RCT (n=96): 4-week Cal/BD followed by 8-week calcipotriol maintenance (Group A) vs. 12-week calcipotriol (Group B). Group A: superior response (p<0.001 weeks 2/4), maintained efficacy; Skindex-29 improved 60%. Relapse: 15% vs. 35%.

52-week extensions confirm <10% withdrawal due to AEs, with proactive twice-weekly application preventing relapse in 80%.

Safety and Tolerability Profiles

Across 20+ trials (>10,000 patients), Cal/BD shows low AE rates:

• Common AEs: Application-site irritation (6-8%), folliculitis (2%).
• Serious AEs: <1%, no systemic corticosteroid effects (PIT levels normal).
• Special Populations: Safe in elderly, no hypercalcemia risk with <100g/week.

Exclusions: infections, atrophic skin. Pregnancy: Category C, avoid.

Quality of Life and Patient-Reported Outcomes

DLQI improvements: 70-80% reduction by week 4. Pooled phase 3 data: Cal/BD gel superior to monotherapies (p<0.01). Skindex-29: marked gains in emotional/social domains.

Recent Advances and Foam Comparisons

2021 review (Armstrong et al.): Foam formulation faster (PGA success week 4: 38% foam vs. 22% gel week 8), but gel remains standard for scalp. PAD-cream trials: comparable to foam via MAIC analysis.

Frequently Asked Questions (FAQs)

Q: How quickly does Cal/BD ointment/gel work?

A: Significant PASI reduction (38-41%) by week 1; 50-70% clear/almost clear by week 4.

Q: Is Cal/BD safe for long-term use?

A: Yes, up to 52 weeks with intermittent regimen; low relapse, minimal AEs.

Q: Which is better for scalp psoriasis: gel or ointment?

A: Gel preferred for better spreadability and patient adherence.

Q: Can Cal/BD be used in children?

A: Approved >12 years; safety data limited, consult dermatologist.

Q: What if I experience skin irritation?

A: Mild/transient; reduce frequency or pause. <5% discontinue.

Clinical Recommendations

Start once-daily for 4 weeks, then maintenance. Combine with phototherapy for severe cases. Monitor calcium in high-dose use.